Mumbai, India, January 24, 2024: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2024.

Financial Summary (All numbers in INR Mn., except Margins)

 Financial and Business Summary for Q3FY25

• The Company voluntarily paused the production at the Gagillapur plant in Sep-24 for risk assessment on account of the US FDA observations. Subsequently, the production resumed in October in a staggered manner.
• Revenue from Operations of Q3FY25 stood at INR 11,377 , a decline of 2% YoY.
• Revenue share from North America increased to 77% in Q3 FY25, compared to 66% in Q3 FY24.
• Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 76%, 12%, and 12% of revenue from operations respectively for Q3FY25.
• ROCE for Q3 FY 25 is at 4% as compared to 15.3% for Q3 FY 24.
• Net debt stood at INR 8,289 and Net debt to EBITDA ratio was 0.90.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur. Progress on our greenfield formulation expansion at GLS remains on track, reinforcing our capabilities and driving future growth.”